Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women
- PMID: 3624413
- DOI: 10.1210/jcem-65-3-541
Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women
Abstract
Two different single doses (400 and 600 micrograms) of the new long-acting dopamine agonist cabergoline (CBG) were given to 12 normal cycling women, 17 puerperal women, and 24 hyperprolactinemic women (12 with idiopathic hyperprolactinemia and 12 with pituitary adenoma). Plasma PRL was determined in blood samples collected before and at frequent intervals for 5 days after CBG administration. Both CBG doses induced marked inhibition of PRL secretion in all women. A decrease in plasma PRL levels was evident 1-2 h after CBG administration and persisted for up to 5 days. The 600-micrograms CBG dose had a more potent (P less than 0.05) PRL inhibitory effect than the 400-micrograms dose in normal, puerperal, and hyperprolactinemic women. Moreover, while 400 micrograms CBG prevented lactation in 3 of 7 puerperal women, 600 micrograms CBG prevented lactation in 5 of 5 puerperal women. A moderate blood pressure decrease occurred 3-6 h after CBG treatment, but no other side-effects occurred. These results demonstrate that CBG induces a dose-related inhibition of PRL secretion in normal women as well as in puerperal and hyperprolactinemic women. The potent long-lasting PRL inhibitory effect of CBG in conjunction with the absence of side-effects typical of dopaminergic compounds suggest that this drug is an advance in the medical treatment of hyperprolactinemia.
Similar articles
-
Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.Drugs. 1995 Feb;49(2):255-79. doi: 10.2165/00003495-199549020-00009. Drugs. 1995. PMID: 7729332 Review.
-
Cabergoline: a new drug for the treatment of hyperprolactinaemia.Hum Reprod. 1995 Jul;10(7):1647-52. doi: 10.1093/oxfordjournals.humrep.a136149. Hum Reprod. 1995. PMID: 8582955 Review.
-
Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline.Obstet Gynecol. 1988 Mar;71(3 Pt 1):311-4. Obstet Gynecol. 1988. PMID: 3279351 Clinical Trial.
-
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.J Clin Endocrinol Metab. 1988 Jan;66(1):193-8. doi: 10.1210/jcem-66-1-193. J Clin Endocrinol Metab. 1988. PMID: 3275684 Clinical Trial.
-
Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.J Clin Endocrinol Metab. 1989 Jun;68(6):1201-6. doi: 10.1210/jcem-68-6-1201. J Clin Endocrinol Metab. 1989. PMID: 2656736 Clinical Trial.
Cited by
-
Is Cabergoline Safe and Effective for Postpartum Lactation Inhibition? A Systematic Review.Int J Womens Health. 2020 Mar 9;12:159-170. doi: 10.2147/IJWH.S232693. eCollection 2020. Int J Womens Health. 2020. PMID: 32210637 Free PMC article. Review.
-
Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.J Int AIDS Soc. 2019 Jun;22(6):e25322. doi: 10.1002/jia2.25322. J Int AIDS Soc. 2019. PMID: 31183987 Free PMC article. Review.
-
A retrospective drug use evaluation of cabergoline for lactation inhibition at a tertiary care teaching hospital in Qatar.Ther Clin Risk Manag. 2016 Feb 9;12:155-60. doi: 10.2147/TCRM.S96298. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 26929627 Free PMC article.
-
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.J Endocrinol Invest. 1997 Oct;20(9):547-51. doi: 10.1007/BF03348017. J Endocrinol Invest. 1997. PMID: 9413809
-
Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.Drugs. 1995 Feb;49(2):255-79. doi: 10.2165/00003495-199549020-00009. Drugs. 1995. PMID: 7729332 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous